{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T15:59:18Z","timestamp":1773763158005,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,17]]},"DOI":"10.7759\/cureus.105353","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T14:07:14Z","timestamp":1773756434000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical Characteristics, Prognostic Factors, and Outcomes of Patients With Medullary Thyroid Carcinoma: A Retrospective Review From a Tertiary Care Hospital"],"prefix":"10.7759","author":[{"given":"Sidra","family":"Aslam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waqas","family":"Shafiq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Imran","family":"Siddiqi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anum","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells SA Jr","year":"2015","unstructured":"Wells SA Jr, Asa SL, Dralle H, et al.. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015, 25:567-610. 10.1089\/thy.2014.0335","journal-title":"Thyroid"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22244","article-title":"Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases","volume":"107","author":"Roman S","year":"2006","unstructured":"Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006, 107:2134-42. 10.1002\/cncr.22244","journal-title":"Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-22542-5_3","article-title":"Epidemiology and clinical presentation of medullary thyroid carcinoma","author":"Raue F","year":"2015","unstructured":"Raue F, Frank-Raue K. Epidemiology and clinical presentation of medullary thyroid carcinoma. Medullary Thyroid Carcinoma. Recent Results in Cancer Research. Springer, Cham; 2015. 204:61-90. 10.1007\/978-3-319-22542-5_3"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1094242","article-title":"Early postoperative calcitonin-to-preoperative calcitonin ratio as a predictive marker for structural recurrence in sporadic medullary thyroid cancer: a retrospective study","volume":"13","author":"Jiao Z","year":"2022","unstructured":"Jiao Z, Wu T, Jiang M, et al.. Early postoperative calcitonin-to-preoperative calcitonin ratio as a predictive marker for structural recurrence in sporadic medullary thyroid cancer: a retrospective study. Front Endocrinol (Lausanne). 2022, 13:1094242. 10.3389\/fendo.2022.1094242","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-1714","article-title":"Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study","volume":"93","author":"Elisei R","year":"2008","unstructured":"Elisei R, Cosci B, Romei C, et al.. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab. 2008, 93:682-7. 10.1210\/jc.2007-1714","journal-title":"J Clin Endocrinol Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1998.00392.x","article-title":"Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients","volume":"48","author":"Modigliani E","year":"1998","unstructured":"Modigliani E, Cohen R, Campos JM, et al.. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. Clin Endocrinol (Oxf). 1998, 48:265-73. 10.1046\/j.1365-2265.1998.00392.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0044","article-title":"Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma","volume":"90","author":"Barbet J","year":"2005","unstructured":"Barbet J, Campion L, Kraeber-Bod\u00e9r\u00e9 F, Chatal JF. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2005, 90:6077-84. 10.1210\/jc.2005-0044","journal-title":"J Clin Endocrinol Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2009.03666.x","article-title":"Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis","volume":"72","author":"Meijer JA","year":"2010","unstructured":"Meijer JA, Le Cessie S, Van Den Hout WB, Kievit J, Schoones JW, Romijn JA, Smit JW. Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis. Clin Endocrinol (Oxf). 2010, 72:534-42. 10.1111\/j.1365-2265.2009.03666.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2534","article-title":"Biological relevance of medullary thyroid microcarcinoma","volume":"97","author":"Machens A","year":"2012","unstructured":"Machens A, Dralle H. Biological relevance of medullary thyroid microcarcinoma. J Clin Endocrinol Metab. 2012, 97:1547-53. 10.1210\/jc.2011-2534","journal-title":"J Clin Endocrinol Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0142(20000301)88:5%3C1139::aid-cncr26%3E3.0.co;2-z","article-title":"Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems","volume":"88","author":"Kebebew E","year":"2000","unstructured":"Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000, 88:1139-48. 10.1002\/(sici)1097-0142(20000301)88:5%3C1139::aid-cncr26%3E3.0.co;2-z","journal-title":"Cancer"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.1002\/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1","article-title":"A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995","volume":"83","author":"Hundahl SA","year":"1998","unstructured":"Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer. 1998, 83:2638-48.","journal-title":"Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.6075","article-title":"Prediction of lateral lymph node metastases in medullary thyroid cancer","volume":"95","author":"Machens A","year":"2008","unstructured":"Machens A, Hauptmann S, Dralle H. Prediction of lateral lymph node metastases in medullary thyroid cancer. Br J Surg. 2008, 95:586-91. 10.1002\/bjs.6075","journal-title":"Br J Surg"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e318268301d","article-title":"Prognostic impact of N staging in 715 medullary thyroid cancer patients: proposal for a revised staging system","volume":"257","author":"Machens A","year":"2013","unstructured":"Machens A, Dralle H. Prognostic impact of N staging in 715 medullary thyroid cancer patients: proposal for a revised staging system. Ann Surg. 2013, 257:323-9. 10.1097\/SLA.0b013e318268301d","journal-title":"Ann Surg"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-80396-3_11","article-title":"Long-term follow-up in medullary thyroid carcinoma patients","author":"Raue F","year":"2025","unstructured":"Raue F, Frank-Raue K. Long-term follow-up in medullary thyroid carcinoma patients. Medullary Thyroid Carcinoma. Recent Results in Cancer Research. Springer, Cham; 2025. 223:10.1007\/978-3-031-80396-3_11"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2012.38","article-title":"Advances in the follow-up of differentiated or medullary thyroid cancer","volume":"8","author":"Elisei R","year":"2012","unstructured":"Elisei R, Pinchera A. Advances in the follow-up of differentiated or medullary thyroid cancer. Nat Rev Endocrinol. 2012, 8:466-75. 10.1038\/nrendo.2012.38","journal-title":"Nat Rev Endocrinol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-07-0667","article-title":"Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times","volume":"158","author":"Laure Giraudet A","year":"2008","unstructured":"Laure Giraudet A, Al Ghulzan A, Aup\u00e9rin A, et al.. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol. 2008, 158:239-46. 10.1530\/EJE-07-0667","journal-title":"Eur J Endocrinol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells SA Jr","year":"2012","unstructured":"Wells SA Jr, Robinson BG, Gagel RF, et al.. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012, 30:134-41. 10.1200\/JCO.2011.35.5040","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei R","year":"2013","unstructured":"Elisei R, Schlumberger MJ, M\u00fcller SP, et al.. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013, 31:3639-46. 10.1200\/JCO.2012.48.4659","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/339646-clinical-characteristics-prognostic-factors-and-outcomes-of-patients-with-medullary-thyroid-carcinoma-a-retrospective-review-from-a-tertiary-care-hospital","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T14:07:15Z","timestamp":1773756435000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/339646-clinical-characteristics-prognostic-factors-and-outcomes-of-patients-with-medullary-thyroid-carcinoma-a-retrospective-review-from-a-tertiary-care-hospital"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.105353","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,17]]}}}